Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$1.92 USD
-0.03 (-1.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
EBS 1.92 -0.03(-1.54%)
Will EBS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EBS
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
Other News for EBS
Emergent Biosolutions Enhances Executive Retention Bonuses
FDA approves Amneal's generic version of OTC Narcan
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
Analysts’ Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)
Commit To Purchase Emergent BioSolutions At $2, Earn 37.8% Annualized Using Options